IL-2 (interleukin 2)

DRUG3 trials

Sponsors

King's College London, Qingdao Sino-Cell Biomedicine Co., Ltd., Peking University People's Hospital

Conditions

Advanced Non-Small Cell Lung CancerLiver DiseasesNeuromyelitis Optica Spectrum Disorder (NMOSD)Transplantation

Phase 1

HS-IT101 Injection for Advanced NSCLC

Not yet recruitingNCT07105176

Qingdao Sino-Cell Biomedicine Co., Ltd.Advanced Non-Small Cell Lung Cancer

Start: 2025-08-30End: 2027-08-30Target: 12Updated: 2025-08-19

Phase 2

Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder

Not yet recruitingNCT07809724

Peking University People's HospitalNeuromyelitis Optica Spectrum Disorder (NMOSD)

Start: 2026-08-30End: 2028-12-30Target: 60Updated: 2026-09-09

Phase 4

Low-dose IL-2 for Treg Expansion and Tolerance (LITE)

TerminatedNCT02949492

King's College LondonTransplantation, Liver Diseases

Start: 2017-12-12End: 2019-01-31Updated: 2019-08-14

Related Papers

Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans.

2022-09-0751 citations